Skip to main content
Presentation
View our ESMO GI 2026 presentation by visiting our publications page

Publications

Publishing the Frontiers of Immuno-Oncology

Spotlight Publication

Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)

Botensilimab ± Balstilimab in Patients with Advanced Cutaneous Melanoma Refractory/Resistant to Anti–PD-(L)1 ± CTLA-4: A Phase 2 Trial

May 31, 2026
,
Atkins, M. et al.
ASCO
Phase II Trial
Melanoma
View Publication
All Molecules
This is some text inside of a div block.
All Conferences
This is some text inside of a div block.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Clinical Trials
Clear all filters
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Phosphopeptide Targets

Molecular mechanism of phosphopeptide neoantigen immunogenicity

Other Articles & Publications
Nature Communications
June 23, 2023
,
No items found.
Read Now
Download Now
View Publication
AGEN2373 (CD137 Agonist)

A Phase 1 Study of AGEN2373, a Novel CD137 Agonist Antibody Designed to Avoid Hepatoxicity, in Patients with Advanced Solid Tumors

ASCO
American Society of Clinical Oncology (ASCO)
June 3, 2023
,
Barve et al.
No items found.
Read Now
Download Now
View Presentation
Botensilimab (Fc-enhanced anti-CTLA-4)

Accelerating the Evolution of Immune-Related Enterocolitis Management

ASCO
Journal of Clinical Oncology
April 11, 2023
,
No items found.
Read Now
Download Now
View Publication
Botensilimab (Fc-enhanced anti-CTLA-4)
Balstilimab (PD-1 inhibitor)

Botensilimab, a novel innate/adaptive immune activator, plus balstilimab(anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer

SGO
Society of Gynecologic Oncology (SGO)
March 27, 2023
,
Bockorny B, et al.
Ovarian
Read Now
Download Now
View Presentation
Agenus Inc.
3 Forbes Road
Lexington, MA 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200
Our Science
Pipeline
Publications
Clinical Trials
Immunotherapy
About BOT + BAL
Company
Our History
Our Team
Careers
Partners
Access
Patient Access
Contact Medical Affairs
Resources
Press Releases
In the News
Patient Resources
FAQs
Investors
Investor Overview
Events
Financial Information
Opt-out preferencesCookie PolicyTerms and Conditions of UsePrivacy PolicyCommunity GuidelinesAccess to Investigational Medicines PolicyReport Adverse EventInvestor Portal
© 2025 Agenus Inc. All rights reserved.